US Stem Cell Inc (USRM)

[Dragon Lady]

BMAK and CDEL both moved back down on that Ask now at .105 and Bid now dropped back to sub ONE CENT

Looks like "that's it folks" IMO, not likely going any higher than that .0105 then- unless those two move way back off the Ask as they did for two "breather days"

0.01 / 0.0105 (200000 x 289986)

http://www.otcmarkets.com/stock/BHRT/quote

Just went RED back to ONE CENT, as expected. If BMAK is parked on the Ask w/ that 10K share block at .0105, not gonna break that IMO, not for now at least. BMAK and CDEL just loaded down the Ask/Sell-side.

Oh, but wait- there's gonna be "big news" when they re-start the MARVEL phase III, LOL !!! Oh yeah, which part of the $36K or which part of the next $25K toxic, convertible note deal (they did THREE so far in just Jan/Fab of 2015) or which part of a $100K Magna credit line draw (cost um 19 MILLION dilution shares for the first draw, plus 9 million more in Magna "fees") which part of that big ole money pile is gonna pay for an imaginary phase III trial "re-start"?? LOL !!

Oh, yeah- the big year with the big sales of 2014 and they ended with less cash on hand than in 2013, a whopping $36K bucks in the bank. But that ole "might/maybe/we could/we hope two/possibly/perhaps/if funded" ole MARVEL trial, going on over 5 YEARS old is right in that "re-start" on-deck circle getting all warmed up to go? That ole money that's not there is just gonna materialize out of nowhere again, like it's supposedly been for the past 5 plus years?

From the just filed 10-K, PAGE 55:

"Research and Development

Research and development expenses were $66,420 in 2014, a decrease of $560,563 from research and development expenses of $626,983 in 2013. The decrease was primarily attributable to a decrease in the amount of available funds.

The timing and amount of our planned research and development expenditures is dependent on our ability to obtain additional financing."

Oh yeah, sounds like big, $10's of MILLIONS for some imaginary "phase III re-start" is just sitting right around that other bend that Yellow Brick Road, LOL ! Sure.

Same just filed 10-K, PAGE 56:

"At December 31, 2014, we had cash and cash equivalents totaling $36,674; our working capital deficit as of such date was $10,957,443. Our independent registered public accounting firm has issued its report dated March 16th, 2015 in connection with the audit of our financial statements as of December 31, 2014 that included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern.

As of December 31, 2014, we had $5,852,790 in outstanding loans."

Oh yeah, over $5 MILLION in outstanding loans and $11 MILLION in total capital deficits with $36K big bucks left in the bank- but that ole "big MARVEL phase III" is almost/maybe/kinda-sorta/perhaps/when funds come in/probably/could-maybe just about to be re-started?? LOL. Right, another fantasy myth IMO. It's been 5 plus yrs of "it's about to be restarted". WHERE'S THE MONEY TO FUND IT? Not there.

Remember a "big phase III" called MIRROR that NEVER HAPPENED? And now just vanished, gone per a one liner in some PR?

Here's the great "sounding" PR's about that ole MIRROR PHASE III, all except the part where it NEVER ACTUALLY HAPPENED and then was cancelled/vanished just recently with no further explanation given:

http://www.marketwired.com/press-release/bioheart-announces-phase-iii-mirror-trial-for-myocell-initiated-otcqb-bhrt-1807938.htm

Wow, FULLY FUNDED BY BIOHEART, "first patient enrolled" LOL, ONE. And then- after 1.5 yrs, a big ole goose egg, NOTHING. Nothing more ever happened.

Then came the ole "big presentation" - and MIRROR is a gonner, never happened, never progressed, never was "FULLY FUNDED BY BIOHEART" as claimed. What a surprise - funny how that happened and just got a lil ole "one liner" no-explanation that it's just done, gone, over now. Kaput. Goodbye. Not happening and never really happened for all intents and purposes IMO.

http://finance.yahoo.com/news/bioheart-updates-diversifies-clinical-development-150000986.html

And here it is- the other supposed "big trials" that went NOWHERE:

Quote from one-line slipped into middle of "grand sounding" ole "PR":

"The Company has no further plans to advance its ANGEL and MIRROR clinical development programs"

LOL, not much to "advance" on ole "MIRROR" when it never actually went anywhere in the first place??

Oh yeah, just waiting on that ole MARVEL "re-start". Q-1 is OVER in a few days- and nothing's changed that I can see. Not a thing. Other than easily 50 MILLION plus dilution shares already in 2015 from just reading the 10-K for Jan/Feb (who knows how many 10's of MILLIONS of shares got issued in just March 2015?) but- Jan, Feb were whopper dilution months and whopper toxic financing deal months just to kick-off 2015 IMO.

Some highlights of just Jan/Feb 2015, most recent, just filed 10-K

PAGE F-34:

"Subsequent financing

On January 7, 2015, the Company entered into a Securities Purchase Agreement with KBM Worldwide, Inc. (“KBM”), for the sale of an 8% convertible note in the principal amount of $38,000 (the “Note”).

The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on October 9, 2015. The Note is convertible into common stock, at KBM’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.

On January 28, 2015, the Company entered into a Securities Purchase Agreement with Fourth Man, LLC., for the sale of an 9.5% convertible note in the principal amount of $25,000 (the “Note”).

The Note bears interest at the rate of 9.5% per annum. All interest and principal must be repaid on January 27, 2016. The Note is convertible into common stock, at Asher’s option, at a 47% discount to the lowest daily closing trading price of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal at 150%, interest and any other amounts.

On February 19, 2015, the Company entered into a Securities Purchase Agreement with Vis Vires Group, Inc. (“VIS”), for the sale of an 8% convertible note in the principal amount of $38,000 (the “Note”).

The Note bears interest at the rate of 8% per annum. All interest and principal must be repaid on November 23, 2015. The Note is convertible into common stock, at VIS’s option, at a 45% discount to the average of the three lowest closing bid prices of the common stock during the 10 trading day period prior to conversion. In the event the Company prepays the Note in full, the Company is required to pay off all principal, interest and any other amounts owing multiplied by (i) 140% if prepaid during the period commencing on the closing date through 179 days thereafter. After the expiration of 180 days following the date of the Note, the Company has no right of prepayment.
"

PAGE F-34:

"Subsequent stock issuances

In January 2015, the Company issued 4,783,568 shares of its common stock in settlement for services, provided 14,299,567 shares of its common stock in settlement of $49,500 of outstanding convertible notes payable, and $2,981 accrued interest and 2,096,450 shares of its common stock for net proceeds of $16,118 from equity drawdown under the Magna Purchase Agreement.

In February 2015, the Company sold an aggregate of 1,443,656 shares of its common stock for net proceeds of $16,270. In connection with the stock sale, the Company issued an aggregate of 1,443,656 warrants to purchase the Company’s common stock for five years at $0.01127 per share. In addition, the Company issued 20,219,367 shares of its common stock in settlement of $132,500 of outstanding convertible notes payable and $2,520 accrued interest and 16,556,976 shares of its common stock for net proceeds of $135,645 from equity drawdown under the Magna Purchase Agreement.

In March 2015, the Company issued 6,185,432 shares of its common stock in settlement of $25,000 of outstanding convertible notes payable and $1,226 accrued interest. In addition, the Company issued 635,357 shares of its common stock as true up shares relating to the February 2015 equity drawdown under the Magna Purchase Agreement."


So lets see- just to "kick off" 2015, how much MASS DILUTION was that approx??

Oh about 4.7 MILLION + 14 MILLION or so + 2 MILLION more + 1.4 MILLION + 20 MILLION more + another little chunk of 16.5 MILLION + oh a tad more of 6 MILLION more or so and then a cool 600K more shares. So what that equal too just for the Jan/Feb MASS DILUTION KICK OFF MONTHS of 2015:

4.7 + 14 + 2 + 1.4 + 20 + 16.5 + 6 + .6 = approx 65 MILLION SHARES OF PURE FREE TRADING DILUTION in just Jan/Feb of 2015.

And then a whole slew of toxic, "convertible debt" (floorless) note deals all coming due through the summer months clear till October.

Looking par for the course IMO. MARVEL "re-start"?? Too funny IMO. "India" blah, blah "trials news" or whatever? OK, sure. Probably never hear of "India" again IMO, other than maybe a line or two that it "went great" or similar.

My 1 CENT worth this AM